[go: up one dir, main page]

WO2018006939A1 - Vaccin inactivé contre la tuberculose. - Google Patents

Vaccin inactivé contre la tuberculose. Download PDF

Info

Publication number
WO2018006939A1
WO2018006939A1 PCT/EP2016/065799 EP2016065799W WO2018006939A1 WO 2018006939 A1 WO2018006939 A1 WO 2018006939A1 EP 2016065799 W EP2016065799 W EP 2016065799W WO 2018006939 A1 WO2018006939 A1 WO 2018006939A1
Authority
WO
WIPO (PCT)
Prior art keywords
inactivated
gene
isolated microorganism
bcg
tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/065799
Other languages
English (en)
Inventor
Carlos MARTIN MONTAÑÉS
Juan Ignacio AGUILÓ
Santiago URANGA MAÍZ
Esteban RODRIGUEZ SANCHEZ
Eugenia PUENTES COLORADO
Concepción FDEZ. ALVAREZ-SATUALLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofabri SL
Universidad de Zaragoza
Original Assignee
Biofabri SL
Universidad de Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofabri SL, Universidad de Zaragoza filed Critical Biofabri SL
Priority to PCT/EP2016/065799 priority Critical patent/WO2018006939A1/fr
Publication of WO2018006939A1 publication Critical patent/WO2018006939A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Definitions

  • the present invention refers to an inactivated isolated microorganism belonging to the Mycobacterium tuberculosis complex that comprises the deletion or previous disruption of the phoP gene; and a second gene to prevent DIM production. Also it refers to its use as vaccine for the prevention or treatment of tuberculosis and/or bladder cancer. Therefore the present invention belongs to the medical field. BACKGROUND ART
  • Tuberculosis (TB) disease causes one and a half million deaths per year, and is one of the leading infectious diseases affecting mainly developing and underdeveloped countries.
  • the rising spread of multidrug resistant strains with the increasing globalization makes TB an alarming global health problem (Marinova, D., et al., Expert Rev Vaccines, 2013. 12(12): p. 1431 -48). Therefore, there is an urgent need for new effective TB vaccines.
  • Vaccination through the natural route of infection represents an attractive approach in vaccinology for priming the natural host immunity.
  • pulmonary mucosal tissue is the primary site for establishment of infection. It is been well described in different preclinical models that vaccination with BCG by the pulmonary route confers a substantially improved protection in comparison to subcutaneous or intradermal immunization (Aguilo, N., et al., J Infect Dis, 2016. 213(5): p. 831 -9; Lagranderie, M., et al., Tuber Lung Dis, 1993. 74(1 ): p. 38-46 . Indeed in the last few years, it has raised a special interest in exploring new vaccination approaches delivered through pulmonary routes of administration.
  • MTBVAC is a live rationally-attenuated derivative of the M. tuberculosis isolate MT103, which belongs to the Lineage 4 (Euro-American) which is one of the most widespread lineages of M. tuberculosis.
  • MTBVAC contains two independent stable deletion mutations in the virulence genes phoP and fadD26 without antibiotic resistance marker, in accordance to the established by the Second Geneva Consensus (Arbues, A., et al., Vaccine, 2013. 31 (42): p. 4867-73).
  • PhoP is a transcription factor that controls 2% of the genome of M.
  • tuberculosis including production of immunomodulatory cell-wall lipids and ESAT-6 secretion (Gonzalo-Asensio, J., et al., PLoS One, 2008. 3(10): p. e3496).
  • Deletion of fadD26 leads to complete synthesis abrogation of the virulence surface lipids phtioceroldimycocerosates (DIM) (Camacho, L.R., et al., Mol Microbiol, 1999. 34(2): p. 257-67).
  • MTBVAC has been the first and only live attenuated M. tuberculosis vaccine approved to enter in clinical trials. First-in-human MTBVAC clinical trial was conducted successfully in healthy adults in Lausanne (Switzerland) (Spertini, F., et al., Lancet Respir Med, 2015. 3(12): p. 953-62).
  • inactivated whole-cell TB vaccines lose most of their immunogenic and protective potential, in comparison to BCG or other live attenuated vaccines (Collins, D.M., New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex. Immunol Cell Biol, 2000. 78(4): p. 342-8). Nevertheless, likely due to some safety concerns described for BCG under some situations (i.e, immunodeficiencies), different authors have explored diverse inactivated vaccine approaches for TB.
  • Vaccination through the natural route of infection represents an attractive approach in vaccinology for priming the natural host immunity.
  • pulmonary mucosal tissue is the primary site for establishment of infection.
  • vaccines delivered by pulmonary route represent an unique approach in the TB vaccine field as they trigger induction of pulmonary mucosal immune response directly in the target organ of TB infection.
  • IgA-deficient mice are more sensitive to pulmonary challenge with BCG (Rodriguez, A., et al., Vaccine, 2005. 23(20): p. 2565-72), suggesting a role for IgAs in mycobacterial infections, which could result an advantage for IgA- inducing vaccines.
  • the present invention discloses a novel vaccine that comprises an inactivated isolated microorganism belonging to the Mycobacterium tuberculosis complex.
  • the inactivated (dead) isolated microorganism belonging to the M. tuberculosis complex that comprises the deletion or previous disruption of the phoP gene and the fadD26 gene when administered after Bacille Calmette-Guerin (BCG) confers more protection than the BCG alone or the alive isolated microorganism against TB.
  • BCG Bacille Calmette-Guerin
  • the administration of MTBVAC+ by intranasal route presents better results than the subcutaneous administration.
  • the results obtained with the inactivated M. tuberculosis of the present invention support that this vaccine approach confers superior protection in comparison to other whole inactivated mycobacteria that contain the genes phoP and fadD26.
  • the vaccine of the present invention is exemplified by an inactivated version of the live attenuated M. tuberculosis vaccine MTBVAC (Arbues A, et al. Vaccine 2013 31 (42):4867-73; Kamath AT, et al. Vaccine 2005 23(29):3753- 61 ), called MTBVAC+.
  • This vaccine shows great efficacy when given by intranasal route in mice previously vaccinated with subcutaneous BCG.
  • phoP and fadD26 deletions in MTBVAC+ are crucial for protection, as the parental strain MT103 (which contains phoP and fadD26 genes) inactivated in the same conditions as MTBVAC+, and administered to mice similarly to MTBVAC+, results unable to improve BCG-induced protection.
  • MTBVAC+ given by the intranasal route as BCG booster induces specifically the generation of specific mucosal immunoglobulins type A (IgA), therefore, it is demonstrated the role of the vaccine of the present invention in protective efficacy.
  • a first aspect of the present invention an inactivated isolated microorganism belonging to the M. tuberculosis complex that comprises the deletion or previous disruption of:
  • a second gene to prevent DIM production preferably wherein this second gene is selected from the list that consists of: fadD22, fadD26, fadD28, ddrC and mmpL7 gene; more preferably is the fadD26 gene.
  • the inactivated isolated microorganism of the first aspect of the invention is also referred to as “the microorganism of the invention” or "the microorganism of the present invention”.
  • the present invention has been exemplified by the M. tuberculosis microorganism and the results can be extrapolated to other members of the M. tuberculosis complex.
  • members of the M. tuberculosis complex including M. tuberculosis (the main causative agent of TB in humans), M. bovis (responsible for TB in cattle and including BCG strain) M. africanum (the main cause of TB in Africa), M. microti, M. caprae, M. pinnipedii, and M. Canetti, represent a single species because of the similarities between them (Cole ST, et al.
  • the microorganism of the present invention is M. tuberculosis isolate MT103.
  • the term "disruption” is the interruption of the gene expression by any method known to those skilled in the art, such as by inserting a marker or antibiotic resistance gene.
  • the term “deletion” refers to the removal of a part of a gene or an entire gene that causes that the expression of said gene and the deleted strain phenotype is lost.
  • the term gene "phoP' refers to the gene known as Rv0757 by the skilled artisan.
  • the gene refers to the gene with GenBank reference number NC_000962.3; in the case of strain M. bovis AF2122/9, to the gene with GenBank reference number NC_002945.3, gene identification 1092447 (GenBank); and in the case of M. africanum GM041 182 strain, with the gene GenBank reference number NC_015758.1 and gene identification 1095513 (GenBank).
  • genes that prevent (avoid) the production of DIM are known to the skilled person (for example, those described in Camacho LR, et al. J Biol Chem. 2001 276 (23): 19845- 54). These genes can be selected from the list comprising: fadD26, fadD28, ddrC and mmpL7. In a particular embodiment fadD26 gene is the preferred one (known by the skilled person as Rv2930). For example, the fadD26 gene of M. tuberculosis H37Rv strain of reference number GenBank NC_000962.3, in the case of strain M.
  • GenBank AF2122/97 gene with GenBank reference number NC_002945.3 1 ,092,151 gene identification (GenBank) and in the case of M. africanum GM041 182 strain with the gene GenBank reference number NC_015758.1 and 10956394 gene identification number (GenBank).
  • the microorganism of the present invention can have also other genes deleted or inactivated, for example the erp gene. It is known by the expert in the field that the erp gene is present in various members of the M. tuberculosis complex and it shares similarities among them (Berthet FX, et al. Science 1998 October 23; 282 (5389): 759-62; Bigi F, et al. Tuberculosis (Edinb) 2005 Jul; 85 (4): 221 -6).
  • the term gene "erp” is the gene known for the skilled person as Rv3810, also known as PIRGS. For example, in the case of M.
  • tuberculosis H37Rv strain it refers to gene GenBank reference number L38851 .1 ; NC_002755.2 in case of M. tuberculosis CDC1551 strain; in the case of M. bovis strain AF2122 / 97, to the gene with GenBank reference number NC_002945.3, gene identification 1093509 (GenBank); and in the case of M. africanum GM041 182 strain, with the gene GenBank reference number NC_015758.1 , 10957490 identification gene (GenBank).
  • the microorganism of the invention may or may not include antibiotic resistance markers, such as kanamycin resistance marker.
  • any type of inactivation procedure can be used for inactivating the microorganism of the present invention as long as the treatment leaves the population of bacteria unable to produce a productive infection at the host, while at the same time preserving antigenic structures necessarily for eliciting a productive response to the corresponding disease-causing mycobacterium.
  • the mycobacterium preparation is typically incapacitated.
  • incapacitated in the context of an incapacitated bacterial cell produced according to the invention, is meant that the bacterial cell is in a state of irreversible bacteriostasis.
  • the bacterium retains its structure-and thus retains, for example, the immunogenicity, antigenicity, and/or receptor-ligand interactions associated with a wild-type bacterium-it is not capable of replicating. In some embodiments, it is incapable of replication due to the presence of an infecting phage with in the bacterial cell.
  • a preferred embodiment of the first aspect of the present invention refers to the inactivated isolated microorganism wherein is inactivated by heat, fixation (for example by formalin) or radiation; preferably by heat.
  • the microorganism can also be inactivated by osmotic pressure via salts, freezing or drying process.
  • a preferred type of inactivation is gamma-irradiation.
  • Other types of inactivation known in the art include, e.g. ultra-violet irradiation.
  • the inactivated isolated microorganism refers to the inactivated isolated microorganism wherein the inactivated isolated microorganism is a whole cell, a cell lysate or cell fragments, or combination of them.
  • cell fragments can be: suitable components include whole cell lysate, culture filtrate proteins, cell wall fraction, cell membrane fraction, cytosol fraction, soluble cell wall proteins, and soluble protein pool.
  • the inactivated isolated microorganism is selected from the following list: M. tuberculosis, M. bovis, M. africanum, M. caprae, M. pinnipedii, M. canetti or M. microti, preferably is M. tuberculosis.
  • the present invention also relates to the use of the microorganism of the first aspect of the invention and a pharmaceutical composition that comprises it for the same indications that one skilled in the art knows to BCG. Therefore, the microorganism of the invention and the pharmaceutical composition that comprises it can be used for the treatment or prevention of TB , for the treatment against bladder cancer (Lamm DL, et al. The Journal of Urology 2000; 163: 1 124-1 129; Saint F, et al. European Urology 2003; 43 351 -361 ), and as an adjuvant or vector (Stover CK, et al. Nature 1991 ; 351 (6.): 456- 460 and Bastos RG, et al. Vaccine 2009; 27: 6495-6503).
  • At least 90% of the M. tuberculosis complex cells are inactivated, e.g., 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, or 100% of the M. tuberculosis complex cells (preferably M. tuberculosis).
  • 100% of the cells are preferably inactivated.
  • a second aspect of the present invention refers to the inactivated isolated microorganism of the first aspect of the present invention for use as a medicament.
  • the present invention refers to the use of the inactivated isolated microorganism for the manufacture of a medicament.
  • a third aspect of the present invention refers to the inactivated isolated microorganism for use in the prevention or treatment of TB in a subject, preferably a mammal, more preferably a human. Therefore, the present invention refers to the use of the inactivated isolated microorganism for the manufacture of a medicament for the prevention or treatment of TB in a subject, preferably a mammal, more preferably a human.
  • the term "subject" comprises any mammal, preferably a human being, man or woman of any age.
  • the subject can also be an individual at risk of immunosuppression, carrier of HIV, or has impaired cellular immunity (by solid organ transplantation, lymphomas, chronic renal failure, for example) or that has other causes of immunosuppression as solid tumors and leukemias.
  • the individual is a newborn with or without risk of immunosuppression and may also be a HIV carrier newborn.
  • the subject can be also a pregnant animal prior to birth to increase production of hyper immune colostrum.
  • the present invention also refers to the uses of the inactivated isolated microorganism of the first aspect of the invention and the pharmaceutical composition that comprises it for veterinary uses, therefore the subject can be any other mammal. More preferably the mammal includes, but is not limited to, a pet, a primate or a ruminant; in the context of the present invention, the individual is preferably a goat, cow, bull, sheep, reindeer, horse, deer, cat or dog.
  • a fourth aspect of the present invention refers to the inactivated isolated microorganism for use in the prevention or treatment of bladder cancer in a subject, preferably a mammal, more preferably a human.
  • the present invention refers to the use of the inactivated isolated microorganism for the manufacture of a medicament for the prevention or treatment of bladder cancer in a subject, preferably mammal, more preferably a human.
  • a fifth aspect of the present invention refers to the inactivated isolated microorganism for use as a vector or as adjuvant.
  • the term "vector” refers to that the inactivated microorganism of the invention may comprise other vaccine antigens from other infectious diseases such as diphtheria, tetanus, pertussis, or degenerative diseases such as amyotrophic lateral sclerosis and others.
  • the term "adjuvant” refers to an agent, which can stimulate the immune system by increasing its response to a vaccine.
  • the microorganism of the present invention can be used as an adjuvant to other vaccine antigens from other infectious diseases such as diphtheria, tetanus, pertussis, or degenerative diseases such as amyotrophic lateral sclerosis and others.
  • a sixth aspect of the present invention refers to a pharmaceutical composition that comprises the inactivated isolated microorganism of the first aspect of the present invention wherein said composition is formulated for intranasal, mucosal, oral, aerosol or intrapulmonary delivery to a subject, preferably a mammal, more preferably a human.
  • pharmaceutical composition herein refers to any substance used for prevention, diagnosis, alleviation, treatment or cure of any disease.
  • the pharmaceutical composition of the invention can be used either alone or in combination with other pharmaceutical compositions, including vaccines and antiviral.
  • composition refers to an antigenic preparation used to elicit an immune response to disease caused by a bacterium or a virus. It is a preparation of antigens that once inside the body, causes the immune response by antibody production and generates immunological memory producing permanent or temporary immunity.
  • the pharmaceutical composition of the present invention is therefore a vaccine.
  • antiviral refers to any substance that does not permit replication, assembly or virus release, such as interferon or ribavirin.
  • a “disorder” is any condition that would benefit from treatment with the composition of the invention, as described herein.
  • the pharmaceutical composition of the invention may further comprise a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition of the invention may further comprise an adjuvant.
  • an adjuvant for example, known to those skilled in the art.
  • adjuvants may include but are not limited to salts, emulsions (including oil/water compositions), saponins, liposomal formulations, virus particles, polypeptides, pathogen-associated molecular patterns (PAMPS), nucleic acid-based compounds.
  • the adjuvant may be aluminum phosphate, aluminum hydroxide, Freud's adjuvant, squalene, vegetable oils and alum; and being particularly preferred Freund's adjuvant.
  • adjuvants include agents such as immune- stimulating complexes (ISCOMs), synthetic polymers of sugars (CARBOPOL®), aggregation of the protein in the vaccine by heat treatment, aggregation by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA®) used as a block substitute may also be employed.
  • ISCOMs immune- stimulating complexes
  • CARBOPOL® synthetic polymers of sugars
  • Fab pepsin treated antibodies to albumin
  • Fab pepsin treated antibodies to albumin
  • mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria
  • the inactivated microorganism of the present invention may be contained in a mucosal bacterial toxin adjuvant such as the Escherichia coli labile toxi (LT) and cholera toxin (CT) or in CpG oligodeoxynucleotide (CpG ODN), derivatives from LPS such as Monophosphoryl lipid A (MPL), Eurocine L3TM, endogenous and pharmaceutically accepted lipids, immune modulating substances such as cytokines or synthetic IFN-[gamma] inducers such as poly l:C alone or in combination with the above-mentioned adjuvants.
  • a mucosal bacterial toxin adjuvant such as the Escherichia coli labile toxi (LT) and cholera toxin (CT) or in CpG oligodeoxynucleotide (CpG ODN), derivatives from LPS such as Monophosphoryl lipid A (MPL), Eurocine L3TM,
  • micropartides or beads of biocompatible matrix materials include micropartides or beads of biocompatible matrix materials.
  • the micropartides may be composed of any biocompatible matrix materials as are conventional in the art, including but not limited to, agar and polyacrylates, Chitosan or any bioadhesive delivery system which may be used are known in the art.
  • excipient refers to a substance that helps the absorption of the pharmaceutical composition comprising the inactivated isolated microorganism of the invention, and also that helps stabilizing or supporting it in its preparation in the sense of giving consistency, shape, flavor or other functional specific characteristics.
  • the excipients may have the function of holding the ingredients together such as starches, sugars or celluloses, sweeten function dye function, protection function of the drug such as to isolate it from the air and/or humidity; function of filling in a tablet, capsule or any other form of presentation such as dibasic calcium phosphate; disintegrating function to facilitate dissolution of the components and their absorption in the intestine; without excluding other excipients not listed in this paragraph.
  • a “pharmacologically acceptable carrier” refers to those substances or combination of substances known in the pharmaceutical industry, used in the manufacture of pharmaceutical dosage forms and includes, but not limited to, solids, liquids, solvents or surfactants.
  • the vehicle can be inert or have analogous action to any of the compounds of the present invention substance and whose function is to facilitate the incorporation of the drug as well as other compounds, allow better dosage and administration or give consistency and shape the composition pharmaceutical.
  • the presentation is liquid, the vehicle is the diluent.
  • pharmaceutically acceptable means that the compound referenced permitted and evaluated so that no harm to the organisms to which it is administered.
  • composition of the invention may further comprise another active ingredient, such vaccine antigens from other infectious diseases such as diphtheria, tetanus, pertussis, or degenerative diseases such as amyotrophic lateral sclerosis and others.
  • vaccine antigens from other infectious diseases such as diphtheria, tetanus, pertussis, or degenerative diseases such as amyotrophic lateral sclerosis and others.
  • active ingredient means any component that potentially provides pharmacological activity or other different effect in the diagnosis, cure, mitigation, treatment or prevention of a disease, which affects the structure or function of the body of man or other animals.
  • the term includes those components that promote a chemical change in the development of the drug and are present in a modified form that provides the specific activity or effect.
  • the pharmaceutical or drug composition provided by this invention can be provided by any route of administration, for which said composition is formulated in the suitable to the chosen route of administration dosage form. In a preferred embodiment said composition is formulated for intranasal, mucosal, oral, aerosol or intrapulmonary delivery to a subject.
  • a preferred embodiment of the sixth aspect of the present invention refers to the pharmaceutical composition wherein composition is lyophilized, solid or liquid form.
  • the inactivated microorganism of the present invention may be contained in a dry powder formulation such as but not limited to a sugar carrier system, preferably that could include lactose, mannitol, and/or glucose. If desired, the inactivated microorganism of the present invention may be contained in a liposomal formulation.
  • the inactivated microorganism of the present invention may be incorporated into microparticles or microcapsules to prolong the exposure of the antigenic material to the subject animal and hence protect the animal against infection for long periods of time.
  • the microparticles and capsules may be formed from a variety of well-known inert, biocompatible matrix materials using techniques conventional in the art.
  • Suitable matrix materials include for example natural or synthetic polymers such as alginates, poly(lactic acid), poly(lactic/glycolic acid), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyortho esters, polyacetals, polycyanoacrylates, polyurethanes, ethytlene- vinyl acetate copolymers, polystyrenes, polyvinyl chloride, polyvinyl fluoride, polyvinyl imidazole), chlorosulphonated, polyethylene oxide agar and polyacrylates. Examples of techniques for incorporation of materials into microparticles or encapsulation are known by the expert in the field.
  • the inactivated microorganism of the present invention may be contained also in small particles suspended in the water or saline.
  • the pharmaceutical composition of the invention may be administered either in a single dose or repeated dose chosen by the skilled artisan.
  • the subject may be vaccinated at any time.
  • the vaccine may be administered in at least two doses 1 -12 months apart.
  • a preferred embodiment refers to the pharmaceutical composition of the invention for use as a vaccine, as a vector or adjuvant, preferably for the treatment or prevention of TB , and/or for the treatment of bladder cancer.
  • the pharmaceutical composition of the invention is used for treatment or prevention of TB and/or for the treatment of bladder cancer.
  • the inactivated microorganism is present in a therapeutically effective dose.
  • terapéuticaally effective dose refers to the amount of the agent or compound capable of producing a desired effect and will generally be determined by the compounds' characteristics, the route and frequency of administration form thereof and other factors, including age, condition of the patient and the severity of the alteration or disorder.
  • the vaccine can be administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic.
  • the quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to mount an immune response, and the degree of protection desired.
  • Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1 ⁇ g to 1000 ⁇ g, such as in the range from about 1 ⁇ g to 300 ⁇ g, and especially in the range from about 10 ⁇ g to 50 ⁇ g.
  • Another preferred embodiment of the sixth aspect of the present invention refers to the pharmaceutical composition wherein the microorganism is in a dose from the equivalent to 10 3 -10 9 (10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 ) CFU (colony forming units) (as is inactivated, is the equivalent as the CFU before its inactivation), preferably 10 7 CFU.
  • a preferred embodiment of the second, third, fourth and fifth aspect of the present invention refers to the inactivated isolated microorganism for use for simultaneous or sequential use with Bacille Calmette-Guerin (BCG).
  • BCG Bacille Calmette-Guerin
  • the inactivated microorganism and the pharmaceutical composition of the present invention act then as a boosting TB vaccine in patients who have already received BCG or another subunit TB immunostimulant.
  • the BCG used is 10 3 -10 9 CFU (10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 ), preferably 2.5x10 5 for newborns or 5x10 5 CFU for adults and is administered subcutaneously.
  • the time between the BCG and the inactivated microorganism of the present invention can be from 3 months to 2 years, preferably form 6 months to 1 year (6, 7, 8, 9, 10, 1 1 or 12 months).
  • the inactivated microorganism of the present invention can be administered at any age, preferably from 6 years old, more preferably from 7-10 years old (7, 8, 9 years old), preferably by intranasal, oral, mucosal or intrapulmonary delivery.
  • a seventh aspect of the present invention refers to a kit or a device that comprises the inactivated isolated microorganism of the first aspect of the present invention or the pharmaceutical composition of the sixth aspect of the present invention.
  • microorganism of the invention or the pharmaceutical composition can be provided as an aerosol or spray package.
  • the microorganism of the invention or the pharmaceutical composition can be provided as a nose-drop or as an eye-drop package.
  • An eighth aspect of the present invention refers to the use of the kit or device of the seventh aspect as a medicament, as a medicament for the prevention or treatment of TB or bladder cancer, or as a vector or adjuvant.
  • a ninth aspect of the present invention refers to a method to inactivate an isolated microorganism belonging to the M. tuberculosis complex that comprises the deletion or inactivation of:
  • a second gene to prevent DIM production preferably wherein this second gene is selected from the list that consists of: fadD22, fadD26, fadD28, ddrC and mmpL7 gene; more preferably is the fadD26 gene; wherein the isolated microorganism is inactivated by heat, fixation or irradiation; and wherein the inactivation is by heat is performed by heating at 80-120 °C, preferably at 100°C, during 20-50 minutes, preferably during 30 minutes; when the inactivation is performed by fixation by incubation in 0.05- 0.5% formalin during 48 hours; and wherein the inactivation is performed by irradiation is performed by ⁇ -irradiation at 25-35 kGy.
  • the invention provides a method of vaccinating a mammal against TB and/or bladder cancer, wherein the method includes administering to the mammal, preferably a human, the inactivated microorganism of the first aspect of the invention, the pharmaceutical composition of the sixth aspect of the invention or the kit o device of the seventh aspect of the present invention; wherein the vaccination of the subject, preferably mammal, more preferably human, is mucosal, preferably intranasal, aerosol or oral, or intrapulmonary; and wherein the composition comprises an immunologically protective dose when delivered to the host.
  • the administration of the inactivated microorganism of the first aspect of the invention, the pharmaceutical composition of the sixth aspect of the invention or the kit o device of the seventh aspect of the present invention is preformed after BCG or another TB stimulant has been administered to the same subject, preferably it was administered BCG subcutaneously.
  • the concentration of the BCG is 10 3 -10 9 (10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 ), preferably 2.5x10 5 for newborns or 5x10 5 CFU for adults; the vaccine of the present invention is administered at is 10 3 -10 9 (10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 ), preferably 10 7 CFU.
  • the time between the BCG and the inactivated microorganism of the present invention can be from 3 months to 2 years, preferably form 6 months to 1 year.
  • the inactivated microorganism of the present invention can be administered at any age, preferably from 6 years old, more preferably from 7-10 years old.
  • the present invention refers also to a method for testing the vaccine of the present invention in a non-human animal model of TB
  • the animal model can be, e.g., a mouse, guinea pig, rabbit, bovine, or non-human primate.
  • the present invention also refers to a method to determine specific immunity against the inactivated microorganism of the first aspect of the invention in a subject previously administered with the inactivated microorganism of the first aspect of the invention, the pharmaceutical composition of the sixth aspect of the invention or the kit o device of the seventh aspect of the present invention; wherein the administration has been mucosal, preferably intranasal, aerosol or oral, or intrapulmonary; that comprises the detection and/or quantification of IgA in a biological sample of said subject and wherein the detection and/or quantification of IgA in the biological sample of said subject is indicative of specific immunity against the inactivated microorganism of the first aspect of the invention.
  • the method comprises the comparison with a control (positive or negative) in order to find a significant difference. From now on is called "the detection method of the invention".
  • the biological sample can be, for example, without limitation, blood, serum, plasma, saliva, urine, sputum, bronchoalveolar lavage (BAL) and bronchial aspirates (BAS).
  • BAL bronchoalveolar lavage
  • BAS bronchial aspirates
  • detection method in the present invention refers to a method for establishing whether a given sample comprises or includes IgA specific to the inactivated microorganism of the present invention with adequate sensitivity and specificity. Typical intervals detection sensitivity can be between about 20% and about 90% of the maximum signal. The specificity a method is given by the probability of detection is negative in a sample not containing the compound to be detected.
  • the detection and/or quantification is preferably performed by an immunoassay.
  • immunoassay or "immunochemical analysis technique” is an immunochemical assay method in which an antibody that specifically binds to an antigen is used (in the present case an antigen of the IgA to be detected).
  • the immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.
  • Immunoassays include, without limitation, immunological techniques such as ELISA (Enzyme-linked immunosorbent assay), Western blot, RIA
  • DAS-EL ISA Double Antibody Sandwich-ELISA
  • immunoaffinity chromatography test strip or lateral flow lateral-flow immunoassay
  • immunoprecipitation dot-blot
  • radioimmunoassay flow cytometry
  • immunocytochemical and immunohistochemical techniques based on the use of biochips biomarker techniques, biosensor or microarray that include specific antibodies or colloidal precipitation-based formats such as "dipsticks" assays.
  • biochips biomarker techniques biosensor or microarray that include specific antibodies or colloidal precipitation-based formats such as "dipsticks" assays.
  • biosensor or microarray that include specific antibodies or colloidal precipitation-based formats such as "dipsticks" assays.
  • transduction principle immunosensors which can be optical, electrochemical, thermometric or massic.
  • immunosorbent or immunoaffinity extraction systems allowing selective extraction of the analyte within a complex mixture, are also included.
  • biohybrid materials resulting from stable binding of the antibody to a solid support (polymer, inorganic material, metal particles, etc.) and used for the separation or extraction of the analyte from other components of the matrix.
  • Such formats may be heterogeneous or homogeneous, sequential or simultaneous, competitive or noncompetitive.
  • the immunochemical technique is ELISA.
  • ELISA are known different types of ELISA such as direct ELISA, indirect ELISA or sandwich ELISA, competitive or non-competitive.
  • a role in protection of mucosal IgA or other immunoglobulins induced by MTBVAC+ vaccination is demonstrated, therefore, measurement of these immunoglobulins could be used to determine the potency of MTBVAC+ vaccination, which could be crucial to assess potency lot during vaccine production, or to potentially differentiate individuals protected or not in clinic. Therefore, another aspect of the present invention is a method to determine the potency of the vaccination with the microorganism of the present invention that comprises the detection and/or quantification of immunoglobulins induced.
  • mice were vaccinated by the subcutaneous route with BCG Danish vaccine 10 6 CFU for adults (A, B), or 2.5x10 5 for neonates (C, D).
  • BCG Danish vaccine 10 6 CFU for adults
  • C, D 2.5x10 5 for neonates
  • mice were intranasally immunized with 10 7 MTBVAC+ bacteria (except indicated group in panel B with 10 4 ).
  • animals were intranasally challenged with 100 CFU of H37Rv (A, B, C) or 10 4 CFU (D).
  • lung bacterial burden was determined one month post challenge. A representative experiment of at least two independent is shown in each panel.
  • mice Groups of six C57BL/6 mice were vaccinated by the subcutaneous route with BCG Danish vaccine 10 6 CFU. Four weeks later mice were intranasally immunized with 10 7 HK Mt103 or MTBVAC+ bacteria. One month later, animals were intranasally challenged with 100 CFU of H37Rv, and lung bacterial burden was determined one month post challenge. Results from one experiment are shown. Data in the graphs are represented as mean ⁇ SEM. One-way ANOVA with Dunnett's multiple comparison tests were performed to calculate statistical significance. * p ⁇ 0.05; ** p ⁇ 0.01 ; *** p ⁇ 0.001 ; **** p ⁇ 0.0001 . "sc", subcutaneous route; "in”, intranasal; "unvacc”, unvaccinated; "LogCFUs”, logarithm of colony forming units; ⁇ ", heat- killed.
  • Fig. 3 Groups of six C57BL/6 mice were vaccinated by the subcutaneous route with BCG Danish vaccine 10 6 CFU. Four weeks later, mice were intranasally immunized with 10 7 MTBVAC+ bacteria. One month later, animals were euthanized and PPD-specific IgA levels measured in BAL by ELISA as described in materials and methods section. A representative experiment of two independent is shown in each panel. Data in the graphs are represented as mean ⁇ SEM. One-way ANOVA tests with Bonferroni post analysis were performed to calculate statistical significance. * p ⁇ 0.05.. "sc”, subcutaneous route; "in”, intranasal; “unvacc”, unvaccinated; "LogCFUs”, logarithm of colony forming units.
  • Fig. 4 Groups of six C57BL/6 mice were vaccinated by the subcutaneous route with BCG Danish vaccine 10 6 CFU. Four weeks later mice were intranasally immunized with 10 7 MTBVAC bacteria inactivated by heat (A), ⁇ - irradiation (B), or formalin (C). One month later, animals were intranasally challenged with 100 CFU of H37Rv, and lung bacterial burden was determined one month post challenge. Results from one experiment are shown. Data in the graphs are represented as mean ⁇ SEM. One-way ANOVA with bonferroni multiple comparison tests were performed to calculate statistical significance. ** p ⁇ 0.01 ; *** p ⁇ 0.001 ; **** p ⁇ 0.0001 .
  • BCG and H37Rv strains were grown at 37°C in Middlebrook 7H9 broth (BD Biosciences) supplemented with ADC (BD Biosciences) and 0.05% (v/v) Tween-80.
  • BCG and H37Rv suspensions for vaccination or infection were prepared in PBS from glycerol stocks previously quantified.
  • a MTBVAC Arbues, A., et al., Vaccine, 2013. 31 (42): p. 4867- 73
  • liquid culture adjusted to a cellular density of about 2x10 8 CFU per mililiter was inactivated by incubation at 100 degrees during 30 minutes. Heat-killed Mt103 was inactivated following the same conditions.
  • mice All mice were kept under controlled conditions and observed for any sign of disease. Experimental work was conducted in agreement with European and national directives for protection of experimental animals and with approval from the competent local ethics committees.
  • mice Groups of eight to ten weeks-old female C57/BL6 mice (Janvier Biolabs) were vaccinated subcutaneously (100 ⁇ ) with 10 6 CFU of BCG Danish 1331 in PBS.
  • mice Four weeks post-vaccination, in the corresponding groups mice were intranasally vaccinated with the indicated dose of MTBVAC+ or heat-killed Mt103 in 40 ⁇ of PBS.
  • animals were challenged intranasally with 100 CFU of H37Rv virulent strain in 40 ⁇ of PBS.
  • Bacterial load from lungs was determined four weeks post-challenge by plating lung homogenates on 7H1 1 +ADC solid agar medium.
  • mice were subcutaneously vaccinated up to three days post birth with 2.5x10 5 CFU of BCG Danish in 50 ⁇ of PBS. Eight weeks later, indicated animals were intranasally immunized with MTBVAC+ as described above. For survival experiments, animals were intranasally challenged with 10 4 H37Rv CFU. Disease-associated symptoms (including weight, aspect and individual/social behaviour) were monitored twice a week, and mice were humanely euthanized according to pre-established endpoint criteria.
  • mice were euthanized by cervical dislocation. Trachea was cannulated and BAL performed following inoculation of 0.8 ml of ice-cold PBS. Supernatant was separated from cells by centrifugation and frozen at -80°C for further IgA detection analysis.
  • maxisorp ELISA plates NUNC
  • PPD purified-protein derivative
  • Copenhagen purified-protein derivative
  • the plate was blocked with Bovine Serum Albumin 1 % (w/v) in washing buffer for 1 hour at 37°C.
  • PPD-coated plates were incubated with 100 ⁇ of BAL during 90 minutes at 37°C.
  • mice Eight to ten weeks old female C57BL/6 mice were subcutaneously immunized with 10 6 CFU of BCG Danish. Four weeks later, two groups of mice were vaccinated with 10 7 MTBVAC HK bacteria (MTBVAC+) inoculated intranasally or subcutaneously, respectively. To elaborate MTBVAC+, a MTBVAC liquid culture was inactivated following incubation at 100 degrees during 30 minutes. Four weeks after MTBVAC+ administration, animals were challenged intranasally with 100 CFU of the virulent M. tuberculosis strain H37Rv, and one month later mice were sacrificed and lung bacterial load was determined by plating lung homogenates in solid agar medium.
  • MTBVAC+ MTBVAC HK bacteria
  • PDIM phthiocerol dimycocerosate
  • Example 3 MTBVAC+ intranasal boost specifically induces generation of mucosal IgA in respiratory airways.
  • bronchoalveolar lavages (BAL) from immunized mice to assess the presence of IgA in respiratory airways following vaccination.
  • IgAs have been found important in the immune response against different respiratory pathogens, and indeed we previously reported that pulmonary but not subcutaneous live BCG triggered specifically IgA production in respiratory airways (Aguilo, N., et al., J Infect Dis, 2016. 213(5): p. 831 -9).
  • Our data obtained by ELISA revealed a strong and specific induction of M. tuberculosis- specific IgA in the BCG-vaccinated group boosted with intranasal MTBVAC+ ( Figure 3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un micro-organisme isolé inactivé appartenant au complexe Mycobacterium tuberculosis qui comprend la délétion, ou la rupture préalable du gène phoP et d'un second gène pour empêcher la production de DIM. Elle porte également sur son utilisation en tant que vaccin pour la prévention, ou le traitement, de la tuberculose et/ou du cancer de la vessie.
PCT/EP2016/065799 2016-07-05 2016-07-05 Vaccin inactivé contre la tuberculose. Ceased WO2018006939A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/065799 WO2018006939A1 (fr) 2016-07-05 2016-07-05 Vaccin inactivé contre la tuberculose.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/065799 WO2018006939A1 (fr) 2016-07-05 2016-07-05 Vaccin inactivé contre la tuberculose.

Publications (1)

Publication Number Publication Date
WO2018006939A1 true WO2018006939A1 (fr) 2018-01-11

Family

ID=56360402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/065799 Ceased WO2018006939A1 (fr) 2016-07-05 2016-07-05 Vaccin inactivé contre la tuberculose.

Country Status (1)

Country Link
WO (1) WO2018006939A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019210888A3 (fr) * 2018-05-02 2019-12-19 成都卫可信生物科技有限公司 Vaccin contre la tuberculose, procédé de préparation associé, et utilisation associée
EP3797791A1 (fr) * 2019-09-26 2021-03-31 Universidad De Zaragoza Efficacité thérapeutique par administration pulmonaire de mycobactéries atténuées vivantes
US11826411B2 (en) 2018-02-19 2023-11-28 Universidad De Zaragoza Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047225A2 (fr) 1999-02-12 2000-08-17 Eurocine Ab Composition de vaccin
WO2008128065A2 (fr) 2007-04-12 2008-10-23 Jennifer Lighter Vaccin contre la tuberculose et procédé d'utilisation dudit vaccin
WO2015144960A1 (fr) * 2014-03-25 2015-10-01 Universidad De Zaragoza Triple mutant du complexe mycobacterium tuberculosis erp-, phop- et dim-

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047225A2 (fr) 1999-02-12 2000-08-17 Eurocine Ab Composition de vaccin
WO2008128065A2 (fr) 2007-04-12 2008-10-23 Jennifer Lighter Vaccin contre la tuberculose et procédé d'utilisation dudit vaccin
WO2015144960A1 (fr) * 2014-03-25 2015-10-01 Universidad De Zaragoza Triple mutant du complexe mycobacterium tuberculosis erp-, phop- et dim-

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
AGUILO, N. ET AL., J INFECT DIS, vol. 213, no. 5, 2016, pages 831 - 9
ARBUES A ET AL., VACCINE, vol. 31, no. 42, 2013, pages 4867 - 73
ARBUES AINHOA ET AL: "Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuatedM. tuberculosis-based vaccine to enter clinical trials", VACCINE, vol. 31, no. 42, 17 August 2013 (2013-08-17), pages 4867 - 4873, XP028717050, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2013.07.051 *
ARBUES, A. ET AL., VACCINE, vol. 31, no. 42, 2013, pages 4867 - 73
BASTOS RG ET AL., VACCINE, vol. 27, 2009, pages 6495 - 6503
BERTHET FX ET AL., SCIENCE, vol. 282, no. 5389, 23 October 1998 (1998-10-23), pages 759 - 62
BIGI F ET AL., TUBERCULOSIS (EDINB, vol. 85, no. 4, July 2005 (2005-07-01), pages 221 - 6
BROSCH R ET AL., PNAS, vol. 99, no. 6, 2002, pages 3684 - 3689
CAMACHO LR ET AL., J BIOL CHEM, vol. 276, no. 23, 2001, pages 19845 - 19854
CAMACHO LR ET AL., J BIOL CHEM., vol. 276, no. 23, 2001, pages 19845 - 54
CAMACHO LR ET AL., MOL MICROBIOL, vol. 34, no. 2, 1999, pages 257 - 267
CAMACHO, L.R. ET AL., MOL MICROBIOL, vol. 34, no. 2, 1999, pages 257 - 67
COLE ST ET AL., NATURE, vol. 393, 1998, pages 537 - 544
COLLINS, D.M.: "New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex", IMMUNOL CELL BIOL, vol. 78, no. 4, 2000, pages 342 - 8, XP009087667, DOI: doi:10.1046/j.1440-1711.2000.00937.x
COX JS ET AL., NATURE, vol. 402, 1999, pages 79 - 83
DESSISLAVA MARINOVA ET AL: "Recent developments in tuberculosis vaccines", EXPERT REVIEW OF VACCINES, vol. 12, no. 12, 1 December 2013 (2013-12-01), GB, pages 1431 - 1448, XP055225672, ISSN: 1476-0584, DOI: 10.1586/14760584.2013.856765 *
ESTHER BROSET ET AL: "ABSTRACT", MBIO, vol. 6, no. 5, 20 October 2015 (2015-10-20), pages e01289 - 15, XP055303575, DOI: 10.1128/mBio.01289-15 *
FERRERAS ET AL: "Mycobacterial Phenolic Glycolipid Virulence Factor Biosynthesis: Mechanism and Small-Molecule Inhibition of Polyketide Chain Initiation", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 15, no. 1, 27 December 2007 (2007-12-27), pages 51 - 61, XP022428217, ISSN: 1074-5521, DOI: 10.1016/J.CHEMBIOL.2007.11.010 *
GONZALO-ASENSIO, J. ET AL., PLOS ONE, vol. 3, no. 10, 2008, pages E3496
IMAEDA T, INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, vol. 35, no. 2, 1985, pages 147 - 150
KAMATH AT ET AL., VACCINE, vol. 23, no. 29, 2005, pages 3753 - 61
KAUSHAL, D. ET AL., NAT COMMUN, vol. 6, 2015, pages 8533
LAGRANDERIE, M. ET AL., TUBER LUNG DIS, vol. 74, no. 1, 1993, pages 38 - 46
LAMM DL ET AL., THE JOURNAL OF UROLOGY, vol. 163, 2000, pages 1124 - 1129
MARINOVA, D. ET AL., EXPERT REV VACCINES, vol. 12, no. 12, 2013, pages 1431 - 48
RODRIGUEZ, A. ET AL., VACCINE, vol. 23, no. 20, 2005, pages 2565 - 72
SAINT F ET AL., EUROPEAN UROLOGY, vol. 43, 2003, pages 351 - 361
SATTI, I. ET AL., LANCET INFECT DIS, vol. 14, no. 10, 2014, pages 939 - 46
SIMÉONE ROXANE ET AL: "Delineation of the roles of FadD22, FadD26 and FadD29 in the biosynthesis of phthiocerol dimycocerosates and related compounds in Mycobacterium tuberculosis.", THE FEBS JOURNAL JUN 2010, vol. 277, no. 12, June 2010 (2010-06-01), pages 2715 - 2725, XP009191711, ISSN: 1742-4658 *
SOLANS LUIS ET AL: "Hyper-attenuated MTBVACerpmutant protects against tuberculosis in mice", VACCINE, ELSEVIER LTD, GB, vol. 32, no. 40, 25 July 2014 (2014-07-25), pages 5192 - 5197, XP029047311, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2014.07.047 *
SOTO CY ET AL., J. CLIN MICROBIOL, vol. 42, no. 1, 2004, pages 212 - 219
SPERTINI, F. ET AL., LANCET RESPIR MED, vol. 3, no. 12, 2015, pages 953 - 62
STOVER CK ET AL., NATURE, vol. 351, no. 6, 1991, pages 456 - 460
VAN SOOLINGEN D ET AL., INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY 199, vol. 747, no. 4, pages 1236 - 1245
WHITE, A.D. ET AL., CLIN VACCINE IMMUNOL, vol. 20, no. 5, 2013, pages 663 - 72
ZAHRT TC; DERETIC V, PNAS, vol. 98, no. 22, 2001, pages 12706 - 12711

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11826411B2 (en) 2018-02-19 2023-11-28 Universidad De Zaragoza Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
WO2019210888A3 (fr) * 2018-05-02 2019-12-19 成都卫可信生物科技有限公司 Vaccin contre la tuberculose, procédé de préparation associé, et utilisation associée
US11426454B2 (en) 2018-05-02 2022-08-30 Sichuan University Tuberculosis vaccine, preparation method therefor, and use thereof
EP3797791A1 (fr) * 2019-09-26 2021-03-31 Universidad De Zaragoza Efficacité thérapeutique par administration pulmonaire de mycobactéries atténuées vivantes
WO2021058831A1 (fr) * 2019-09-26 2021-04-01 Universidad De Zaragoza Efficacité thérapeutique par administration pulmonaire de mycobactéries atténuées vivantes
CN114845732A (zh) * 2019-09-26 2022-08-02 萨拉戈萨大学 通过肺部递送减毒活分枝杆菌的治疗效果
JP2022550722A (ja) * 2019-09-26 2022-12-05 ウニベルシダッド デ サラゴサ 弱毒生マイコバクテリアの肺送達による治療有効性
JP7720097B2 (ja) 2019-09-26 2025-08-07 ウニベルシダッド デ サラゴサ 弱毒生マイコバクテリアの肺送達による治療有効性

Similar Documents

Publication Publication Date Title
JP5931724B2 (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
JP5165681B2 (ja) タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大
RU2623174C2 (ru) Вакцины и композиции против streptococcus pneumoniae
JP2016166193A (ja) 改変された結核抗原
Hatherill et al. Clinical testing of tuberculosis vaccine candidates
Ruben et al. Influenza in a partially immunized aged population: effectiveness of killed Hong Kong vaccine against infection with the England strain
JP2015038130A (ja) 結核のワクチンおよびその使用方法
JP6655549B2 (ja) 免疫応答を誘導するための新規方法
US20200113991A1 (en) Compositions and Methods for Immunizing Against C. Difficile
US20160228528A1 (en) A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine
CN103796640A (zh) 适于治疗或预防结核的脂质体制剂
Mayo-Smith et al. The live attenuated cholera vaccine CVD 103-HgR primes responses to the toxin-coregulated pilus antigen TcpA in subjects challenged with wild-type Vibrio cholerae
WO2018006939A1 (fr) Vaccin inactivé contre la tuberculose.
US20130266613A1 (en) Outer membrane proteins of histophilus somni and methods thereof
Sam et al. Synthetic particulate subunit vaccines for the prevention of Q fever
Cauchard et al. Assessment of the safety and immunogenicity of Rhodococcus equi-secreted proteins combined with either a liquid nanoparticle (IMS 3012) or a polymeric (PET GEL A) water-based adjuvant in adult horses and foals—identification of promising new candidate antigens
Billeskov et al. Difference in TB10. 4 T‐cell epitope recognition following immunization with recombinant TB10. 4, BCG or infection with Mycobacterium tuberculosis
Li et al. Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization
Bissumbhar et al. Evaluation of diphtheria convalescent patients to serve as donors for the production of anti-diphtheria immunoglobulin preparations
US20230218734A1 (en) Compositions and methods for preventing, controlling and diagnosing mycobacterial infections
Sedaghat et al. Determination of bactericidal activity of serum against Vibrio cholerae outer membrane vesicles in BALB/c mice
Minassian et al. Tuberculosis vaccines: present and future
EP3716995A1 (fr) Polythérapie et prophylaxie contre des infections du tractus génital
Hormozi Activation and immunogenicity of Bordetella pertussis adenylate cyclase toxin
JP2015110681A (ja) 牛にワクチン接種するための組成物および方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16735649

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16735649

Country of ref document: EP

Kind code of ref document: A1